Trixis angustifolia DC. as a potential plant for the co-management of diabetes mellitus and tuberculosis

Anuar Salazar-Gómez; Gustavo G. Flores-Bernal; Fernando Uriel Rojas-Rojas; Omar Merino-Pérez; Lucero Catalán-Gonzalez; Julieta Luna-Herrera; Leticia Garduño-Siciliano; M. Elena Vargas-Díaz

doi:10.1371/journal.pone.0339176

Abstract

Diabetes mellitus and tuberculosis represent two concurrent conditions that have posed significant challenges to global public health. A comprehensive investigation into new strategies for co-managing both conditions is essential, given the possible drug interactions. Trixis angustifolia DC. is a plant commonly used in Mexican traditional medicine and has potential antimycobacterial and hypoglycemic properties. This study aimed to investigate the chemical composition of the ethyl acetate extract of T. angustifolia (TxAcE) and its antimycobacterial, hypoglycemic, and hypolipidemic activities. The structures of the isolated compounds were determined by NMR and mass spectrometry. The in vitro antimycobacterial activity of TxAcE and isolated compounds was determined by the Microplate Alamar Blue Assay. The hypoglycemic and hypolipidemic activities of TxAcE (50, 100, and 200 mg/kg p.o.) were investigated using alloxan-induced diabetes and Triton WR-1339-induced hyperlipidemia models in mice, respectively. The TxAcE and the mixture of two new trixanolides (1a and 1a’) isolated from T. angustifolia exhibited antibacterial activity against M. tuberculosis H37Rv, showing a minimum inhibitory concentration of 6.25 µg/mL. In diabetic mice treated with TxAcE (200 mg/kg) for 15 days, non-fasting blood glucose and LDL-C levels were significantly reduced, while HDL-C levels were increased. Treatment with 50 and 100 mg/kg of the TxAcE reduced TG, VLDL-C, and LDL-C levels and increased HDL-C levels in Triton WR-1339-induced hyperlipidemic mice. These findings suggest that T. angustifolia is a promising source of natural antimycobacterial agents. Combined with its hypoglycemic and hypolipidemic effects, this plant has the potential to be valuable for future research in co-managing both diabetes mellitus and tuberculosis.

Citation: Salazar-Gómez A, Flores-Bernal GG, Rojas-Rojas FU, Merino-Pérez O, Catalán-Gonzalez L, Luna-Herrera J, et al. (2025) Trixis angustifolia DC. as a potential plant for the co-management of diabetes mellitus and tuberculosis. PLoS One 20(12): e0339176. https://doi.org/10.1371/journal.pone.0339176

Editor: Armel Jackson Seukep, University of Buea, CAMEROON

Received: July 5, 2025; Accepted: December 1, 2025; Published: December 31, 2025

Copyright: © 2025 Salazar-Gómez et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information file.

Funding: This study was supported by Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional (SIP-IPN) through a grant awarded to MEV-D (20250942) and to JL-H (20251343). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Diabetes mellitus (DM) remains one of the deadliest non-communicable diseases worldwide, with an estimated mortality of 3.4 million people in 2024 [1]. DM is a heterogeneous metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion and/or insulin action [2]. Hyperglycemia is associated with both chronic inflammatory processes and increased susceptibility to infections. People with uncontrolled DM are associated with alterations in the immune system that increase the risk of developing infectious diseases such as active tuberculosis (TB) caused by Mycobacterium tuberculosis [3,4]. In 2022, it was estimated that 0.37 million TB cases globally were reported in people living with DM [5]. Pharmacological management of hyperglycemia could improve TB treatment in DM patients and prevent many complications associated with both co-morbidity. However, drug-drug interactions and adverse drug reactions represent a common clinical problem during the co-management of DM and TB [6,7]. Several studies based on ethnomedicine have shown that some medicinal plants have antimycobacterial and antidiabetic effects [8–11]. Thus, preclinical investigations of medicinal plants with dual antimycobacterial and antidiabetic effects could provide valuable information for the co-management of DM and TB.

The genus Trixis P. Browne (Asteraceae: Mutisieae) comprises approximately 45 species [12,13], 19 of which occur exclusively in Mexico [14,15]. Many species have been traditionally used in America to treat lung diseases, diabetes, stomach illnesses, rheumatism, wounds, venereal diseases, and to improve blood circulation [16–19]. Trixis plants have attracted the attention of scientists for a long time due to their pharmacological potential [18,20–27] and Trixanolide constituents. Trixanolides, or trixikingolides, are structurally diverse molecules based on a trixane skeleton, which are characteristic secondary metabolites of the genus Trixis. Over 50 trixanolides with various structural patterns have been isolated from Trixis plants [22,26,28–32]. These compounds are interesting constituents that have been widely studied in the Trixis genus. However, few studies have been conducted to identify the biological activities of these compounds. So far, the findings have included antileishmanial and trypanocidal activities [22,26].

Trixis angustifolia DC. (Asteraceae), commonly known as “Hierba del viento,” “Capitana,” or “Montezuma,” is a shrub that grows to a height of 1 to 1.5 m, with leaves that are narrowly lanceolate to nearly linear and yellow flower heads [33]. It is an endemic plant of Mexico, distributed in the central and northern parts of the country [14], and is used in traditional medicine to treat lung diseases, rheumatism, wounds, and fever [34,35]. Recently, we reported the hypoglycemic and hypolipidemic effects of the aqueous extract from the aerial parts of T. angustifolia [24,25] and the antimycobacterial [23] and antinociceptive effects of organic extracts [27]. The main components of T. angustifolia are flavones, with 5,6-dihydroxy-7,8,4’-trimethoxyflavone being the most representative. Regarding trixanolides, no scientific reports have been published on their isolation or identification from this species. Thus, in line with our biological and chemical investigations of T. angustifolia, the present work aimed to investigate the antimycobacterial, hypoglycemic, and hypolipidemic activities of the ethyl acetate extract of T. angustifolia (TxAcE), as well as its chemical composition, with a focus on the isolation of trixanolides. This research provides a scientific basis for future studies on the pharmacological properties of T. angustifolia for co-managing DM and TB.

Materials and methods

Plant material

The plant material used in this study was the same specimen previously collected and documented in our earlier research [23–25,27]. Trixis angustifolia DC. was collected in Durango, Mexico (24°00’10.9“N 103°57’32.3”W) in April 2015. The plant material was authenticated by Professor Manuel Quintos-Escalante, and a specimen was deposited in the Herbarium of the Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, with reference code: Col. M. González y S. Acevedo 2144. The plant was dried at room temperature.

General experimental procedures

¹H and ¹³C NMR spectra were obtained on a Varian NMR System spectrometer at 500 and 125 MHz, respectively. Chemical shifts (δ) are reported in parts per million (ppm) relative to internal tetramethylsilane (Me₄Si, δ0.0) for ¹H NMR and CDCl₃ (δ77.0) for ¹³C NMR. Coupling constants (J) are reported in Hertz (Hz). Multiplicities are indicated by s (singlet), d (doublet), dd (doublet of doublets), ddt (doublet of doublet of triplets), t (triplet), td (triplet of doublets), m (multiplet), ovlp (overlapped with other signals). Peak assignments of the ¹H and ¹³C NMR spectra were confirmed using 2D NMR experiments. HRMS were recorded on a micrOTOF-Q II™ spectrometer (Bruker Daltonics, Billerica, MA, United States) using desorption electrospray ionization-MS in positive mode. All solvents used for extraction and chromatography were purchased from Sigma-Aldrich and distilled before use. Analytical thin-layer chromatography (TLC) was performed using precoated TLC plates with Silica Gel 60-F254 and visualized using combinations of UV and cerium molybdate (Hanessian’s stain). Purification of compounds was performed by column chromatography (CC) on silica gel (Merck 230–400 mesh).

Extraction and isolation

The air-dried powdered aerial parts of T. angustifolia (500 g) were macerated with ethyl acetate (x2) at room temperature for seven days. The resulting extracts were combined, filtered, and evaporated under reduced pressure to yield 24.9 g (4.98%) of residue. Trixanolides were extracted according to the procedure described previously [32], with some modifications. A portion of the crude extract (6 g) was suspended in EtOH (50 ml) at 60 °C, diluted with 50 ml of H₂O, and partitioned successively with hexane and CH₂Cl₂ to afford a CH₂Cl₂ fraction (2.192 g). The CH₂Cl₂ fraction was subjected to CC and eluted with a hexane/EtOAc mixture of increasing polarity from hexane/EtOAc (8:2) to hexane/EtOAc (2:8). Three hundred forty-eight fractions were collected and then grouped into twenty major fractions (A-T) after TLC analysis. The regrouped fraction labeled FQ (187 mg) was redissolved in CH₂Cl₂/hexane and crystallized at room temperature to afford a mixture of the trixanolides 1a and 1a’ as a white amorphous powder (19 mg); HRMS m/z 485.2132 [M + Na]⁺ (calcd. for C₂₅H₃₄O₈Na, 485.2151).

Antimycobacterial activity

Mycobacterial species used and inoculum preparation.

Mycobacterium tuberculosis H37Rv (ATCC 27294) and the nontuberculous mycobacteria Mycobacterium smegmatis mc2 155 (ATCC 700084) were acquired from the American Type Culture Collection. Mycobacterium abscessus smooth (Sm) and rough (Rm) variants were clinical isolates recovered from Mexican patients and identified by conventional microbiological methods.

M. tuberculosis H37Rv was grown in Middlebrook 7H9 broth enriched with 0.2% glycerol and 10% OADC (oleic acid, albumin, dextrose, and catalase) at 37ºC until the log phase growth was reached (2 weeks). Nontuberculous strains were grown in the same conditions in non-enriched Middlebrook 7H9, reaching their log phase growth in 4–7 days. All cultures were adjusted to McFarland No. 1 Tube and diluted 1:10 using the same culture media.

Microplate alamar blue assay.

The antimycobacterial activity of TxAcE and a mixture of 1a and 1a’ (1:1) was tested by the Microplate Alamar Blue Assay (MABA) [37] and reported as Minimum Inhibitory Concentration (MIC) values. TxAcE and a mixture of 1a and 1a’ (1:1) were dissolved in dimethylsulfoxide.

The MABA was performed in 96-well plates in a final volume of 200 µl containing 100 µl of the corresponding culture media and TxAcE or a mixture of 1a and 1a’ (1:1) in concentrations ranging from 200–3.125 µg/mL and 100 µl of each bacterial suspension. The plates were incubated for 2 days for nontuberculous mycobacteria and 5 days for M. tuberculosis H37Rv at 37ºC. Afterward, 20 µl of Alamar blue solution were added to each well, and plates were placed at 37 ºC for 24 h. Bacterial growth was measured by the relative fluorescence units determined in a plate fluorometer (Thermo Labsystems Fluoroskan Ascent FL) at 544 nm excitation and 590 nm emission. The relative fluorescence units obtained from the wells containing only bacterial suspension were considered 100% bacterial growth control.

Experimental animals and ethical considerations

Healthy ICR male and female mice (24 ± 3 g, aged 6–7 weeks) were obtained from PROPECUA, S.A. de C.V., Mexico City. All animals were acclimatized for seven days and maintained under standard laboratory conditions (12-h light/dark cycle, 25 ± 2 °C, and relative humidity of 55–80%), with standard diet and purified water provided ad libitum. All animals involved in this study were treated humanely in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the recommendations of the Mexican Official Norm for Animal Care and Handling (SAGARPA, NOM-062-ZOO-1999) [36]. The health status of the animals was regularly monitored, and every effort was made to minimize animal suffering during the study period. The protocol was approved by the Bioethics Committee of the National School of Biological Sciences of the National Polytechnic Institute (ENCB-IPN), registration number ENCB/CEI/007/2018 CONBIOETICA09CEI03720130520.

For the acute toxicity study, euthanasia criteria were set for animals experiencing severe health decline or uncontrollable distress, including significant weight loss, arching, cyanosis, hypothermia, difficulty moving, difficulty breathing, convulsions, marked behavior changes, fainting, or irreversible organ dysfunction. Any animal showing persistent signs of severe distress or pain would have been euthanized by cervical dislocation in full accordance with ethical guidelines. Since no signs of toxicity were observed in any of the animals, euthanasia was performed at the conclusion of the studies.

For blood collection, a retro-orbital puncture technique was executed under anesthesia via intraperitoneal injection (i.p.) of 1% sodium pentobarbital (50 mg/kg of body weight). At the end of the study period (immediately after blood collection), the animals were promptly and humanely euthanized by cervical dislocation in full compliance with ethical guidelines. The procedure was performed by trained personnel with technical precision to ensure rapid and effective dislocation induction, thereby minimizing pain or distress. Carcasses were disposed of safely and in accordance with established procedures.

Acute toxicity of TxAcE

Acute toxicity was carried out according to Guideline No. 423 provided by the Organisation of Economic Co-operation and Development (OECD), with minor modifications [38]. This procedure minimizes the number of animals required for acute toxicity testing. Three female (nulliparous and non-pregnant) or three male mice were randomly assigned to each of the two experimental groups. The TxAcE, dissolved in a vehicle (Tween 80-H₂O, 0.5%), was administered intragastrically after a 12-h fasting period at a dose of 2000 mg/kg of body weight (bw). The control group received only the vehicle (Tween 80-H₂O, 0.5%). All animals were monitored for the next four hours after administration, then every 24 hours for 14 days for any signs of toxicity or mortality. Observations included changes in weight, skin, fur, eyes, and mucous membranes; effects on the respiratory, circulatory, autonomic, and central nervous systems, as well as on somatic motor activity and behavior patterns. Particular attention was placed on observing tremors, convulsions, salivation, diarrhea, lethargy, sleep, and coma. At the end of the experiment (14 days), all the animals were euthanized by cervical dislocation, in full compliance with ethical guidelines. Macroscopic examination was then performed on the heart, liver, spleen, lung, and kidney.

Hypoglycemic effect of TxAcE

Male mice (24 ± 3 g) were fasted for 18 h, and a hyperglycemic condition was induced by a single injection of alloxan monohydrate (200 mg/kg, i.p.) [39]. After five days, hyperglycemia (fasting blood glucose levels greater than 400 mg/dL) was confirmed using the OneTouch Ultra 2 blood glucose meter (Johnson and Johnson, USA). The blood sampling was done by cleaning the tail with 70% ethanol and then nipping the tip of the tail. A drop of blood was placed on a blood glucose test strip and inserted into a blood glucose meter. A total of 35 mice (28 diabetic mice and seven normoglycemic mice) were used for the experiment. The diabetic mice were randomly divided into four groups (n = 7) and administered intragastrically daily with TxAcE (50, 100, and 200 mg/kg bw) for 15 days. Normoglycemic mice were administered intragastrically daily with vehicle (Tween 80-H₂O, 0.5%). The selection of these extract doses was based on findings from our previous results [24,25]. Control group animals were also treated with the vehicle. Non-fasting blood glucose levels were monitored before daily treatments on days 3, 5, 7, 9, 11, and 15 to assess the anti-diabetic effect. At the end of the experiment (16^th day), the animals were fasted overnight, and blood samples were drawn by puncturing the retro-orbital sinus under anesthesia with sodium pentobarbital. Dry tubes containing collected blood were centrifuged at 13,000 × g for 15 minutes to obtain serum, which was stored at −20°C until the measurement of biochemical parameters.

Hypolipidemic effect of TxAcE

Triton WR-1339-induced hyperlipidemia was carried out as described previously [40]. Overnight fasted mice were randomly divided into five groups of seven animals each and treated as follows: Group I served as a control (vehicle; Tween 80-H₂O, 0.5%). Hyperlipidemia was induced in Groups II to V by a single intraperitoneal injection of Triton WR-1339 (400 mg/kg bw) dissolved in normal saline (pH 7.4). Groups III to V were administered intragastrically with TxAcE (50, 100, and 200 mg/kg bw, respectively) 1 hour before and 22 and 48 hours after the Triton WR-1339 injection. The selection of these extract doses was based on findings from our previous results [24,25]. The second group (hyperlipidemic control) was administered intragastrically with Tween 80-H₂O, 0.5%. At the end of each treatment (4 days), the animals were fasted overnight, and blood samples were drawn by puncturing the retro-orbital sinus under anesthesia with sodium pentobarbital. Dry tubes containing collected blood were centrifuged at 13,000 × g for 15 minutes to obtain serum, which was stored at −20°C until the measurement of biochemical parameters.

Biochemical analysis.

Serum samples were subjected to lipid analysis as described previously [41]. TC, HDL-C, and TG were quantified using the corresponding reaction kits for the automatic Vitalab selectra two instrument (Wiener Lab, Amsterdam, Netherlands). VLDL-C and LDL-C were calculated as follows [42]: VLDL-C = TG/5 and LDL-C = TC− (HDL-C+ VLDL-C).

Statistical analysis

All data are expressed as mean ± standard error of the mean. GraphPad Prism® version 9.0.1 for Windows software (California, USA) was used for statistical analyses. The significance was evaluated using an analysis of variance (ANOVA) and Tukey’s post hoc multiple-comparison test. Significant differences were set at P-values less than 0.05.

Results and discussion

Structural characterization of isolated compounds

Two new trixanolides (1a and 1a’) and one previously known flavone 2 were isolated from the ethyl acetate extract of T. angustifolia (Fig 1). The known compound, 5,6-dihydroxy-7,8,4’-trimethoxyflavone 2, was identified by comparison of spectroscopic data with the literature [23].

Download:

Fig 1. Structures of trixanolides (1a and 1a’) and flavone (2) isolated from T. angustifolia.

https://doi.org/10.1371/journal.pone.0339176.g001

Compounds 1a and 1a’ were obtained as an inseparable mixture, appearing as a white amorphous powder. The ¹H NMR spectrum (Table 1 and S1 Fig) of the mixture of 1a and 1a’ showed two sets of signals in nearly 1:1 ratio, e.g., Me-13 (δ 1.23, s; 1.18, s), H-4 (δ 4.40, td, J = 2.8, 1.4 Hz; δ 4.31, td, J = 2.8, 1.3 Hz), H-12 (δ 5.01, s; δ 4.97, s) and H-15 (δ 6.32, s; δ 6.30, s). The ¹³C NMR spectrum showed 49 carbon signals, most occurring pairwise (Table 1 and S2 Fig). The ESI mass spectrum (S8 Fig) of the mixture of 1a and 1a’ showed the sodium adduct ion peak [M + Na]⁺ at m/z 485.2132 (calcd. for C₂₅H₃₄O₈Na, 485.2151), corresponding to the two isomers with the same molecular formula (C₂₅H₃₄O₈).

Download:

Table 1. ¹H (500 MHz) and ¹³C (125 MHz) NMR data of trixanolides 1a and 1a’ in CDCl_3.

https://doi.org/10.1371/journal.pone.0339176.t001

Despite the high complexity of the NMR spectroscopic data of the mixture due to the structural similarity and proximity of the chemical shifts of the two compounds, the peak assignments of the ¹H and ¹³C NMR spectra of 1a and 1a’ were achieved using 2D NMR experiments (COSY, TOCSY, HSQC, HMBC, and ROESY) (S3–S7 Figs) and by comparison with data in the literature [30]. NMR analyses allowed us to identify the 9,14-diester-12-hydroxytrixanolide skeleton of 1a and 1a’, suggesting that these compounds were analogs of four sets of C-12 epimers isolated earlier from Trixis praestans (Vell.) Cabrera [30]. Since one of the most remarkable changes was the chemical shifts of singlet signals at δ 5.00/4.97 for H-12, these signals were selected as the starting point for the NMR assignments of each compound. The HMBC correlations from H-9/H-15 to C-6, H-1/H-3/H-13 to C-11, H-4/H-10 to C-12, H-1/H-10/H-15 to C-5; and the corresponding 1H-1H COSY correlations from H-1, 2, 3, 9 and H-10 as well as from H-7 via H-8a,b and H-9 to H-10 confirmed the presence of the trixane core (C1-C10) (Fig 2). Unlike the 1:1 mixture of C-12 epimers of trixanolides isolated previously [30], angelate group ((2Z)-2-methylbut-2-enoate) was located at C-9 and the ester group 2-(hydroxymethyl) butanoate at C-14 [δ_C 173.8 (C-16), 49.1 (C-17), 21.5 (C-18), 11.6 (C-19), 62.5 (C-20)]. The distribution of the two acyl groups, angelate and 2-(hydroxymethyl) butanoate, over C-9 and C-14 were supported by the HMBC correlation of H-9 (δ 5.36/5.35) to C-21(δ 166.8) and H-14 (δ 5.54, 5.43) to C-16 (δ 173.8), respectively (S6 Fig). The ¹³C NMR data of the mixture showed duplicated signals for 9,14-diester-12-hydroxytrixanolide skeleton (C1-C14), while no duplication was observed for angelate and 2-(hydroxymethyl)butanoate groups. The relative configuration of 1a and 1a’ was elucidated based on ROESY experiments, and to confirm their observed correlations, a computer-assisted 3D structure was obtained by using the software Spartan 10, V1.0.1, with MMFF94 calculations for energy minimization (Fig 2). Different ROE correlations of each H-12 signal were observed. H-12 in 1a shows spatial coupling with H-3eq, while H-12’ in 1a’ is spatially coupled with H-10’. Based on the above, it was deduced that compounds 1a and 1a’ correspond to the α- and β- isomers of the hydroxy group, differing in the configuration of the hemiacetalic carbon C12, similar to the anomeric carbon in carbohydrates. Additionally, several inseparable epimeric mixtures of trixanolides have been reported in previous works [31,32]. To the best of our knowledge, this is the first report of the isolation of trixanolides from T. angustifolia.

Download:

Fig 2. Selected a) HMBC (→), COSY (bold red line), and b) ROESY (blue ↔) correlations and ³J_(H7,H14) (pink ↔) of trixanolides 1a and 1a’.

The configuration of C17 in the 3D models was arbitrarily assigned.

https://doi.org/10.1371/journal.pone.0339176.g002

Antimycobacterial activity

Traditionally, the aerial parts of T. angustifolia are used to treat lung diseases and fever [33,34]. These uses directed us to investigate the therapeutic potential of T. angustifolia for TB treatment. The results of the microplate MABA showed that TxAcE exhibited a MIC value of 6.25 µg/mL for Mycobacterium tuberculosis H37Rv (Table 2). We previously reported a MIC value of 50 µg/mL for an ethyl acetate extract of T. angustifolia obtained by consecutively extracting the aerial parts with solvents in increasing order of polarity [23]. In the present study, the plant material was subjected to direct maceration with ethyl acetate, which appears to improve the extraction of antimycobacterial compounds.

Download:

Table 2. Minimal inhibitory concentrations (MIC) of the ethyl acetate extract of Trixis angustifolia DC. (TxAcE) and trixanolides (1a and 1a’) against Mycobacterium tuberculosis H37Rv and nontuberculous mycobacteria.

https://doi.org/10.1371/journal.pone.0339176.t002

The inhibitory activity of organic extracts from Asteraceae plants against M. tuberculosis has been previously reported [43–45], indicating the potential of this family as a source of novel compounds for TB treatment. In addition to M. tuberculosis infections, the prevalence of diseases caused by drug-resistant nontuberculous mycobacteria infections has increased worldwide (mainly in industrialized countries) over the past decades, some even bigger than TB prevalence [46]. Within these mycobacteria species, the Mycobacterium abscessus group is one of the common nontuberculous mycobacteria responsible for lung and skin infections in immunocompetent and cystic fibrosis patients [47], which has generated the medical need to discover more effective drugs against this group of mycobacteria. The TxAcE also had antimycobacterial activity against M. abscessus Sm (MIC = 6.25 µg/mL) and Rm (MIC = 12.5 µg/mL). These strains represent the two M. abscessus variants frequently recovered from distinct clinical outcomes [48]. Additionally, M. abscessus is considered one of the most drug-resistant mycobacterial strains [46]; thus, TxAcE could be considered a promising source of new drugs for M. abscessus-infection. We also test TxAcE against the strain Mycobacterium smegmatis mc² 155. The extract showed a MIC value of 50 µg/mL, which is lower than the reported for ethyl acetate extracts from other Asteraceae plants like Ambrosia confertiflora DC. against M. tuberculosis H37Rv [44] and Bidens odorata (Cavanilles). J. against M. smegmatis mc² 155 [45]. This result indicates the potential use of M. smegmatis mc² 155 as a safe and easy-to-handle model for further studies on the mechanisms of action of T. angustifolia antimycobacterial compounds.

In addition to previous work by our group on the antimycobacterial activity of T. angustifolia hexanic extract (TxHxE) with a MIC value of 25 µg/mL [23], the activity of TxAcE described above with lower MIC values contributes to research on natural alternatives using Mexican Trixis species (or isolated compounds) for treating different infectious diseases caused by multiresistant bacteria. Regarding this issue, the mixture of trixanolides 1a and 1a’ (1:1) was also evaluated for its antimycobacterial activity against M. tuberculosis H37Rv. Interestingly, the 1a and 1a’ mixture exhibited significant activity against M. tuberculosis H37Rv with a MIC of 6.25 µg/mL (Table 2). The lower MIC reported in the present work may be due to the use of partially purified molecules rather than the mixture of molecules that composed the TxHxE.

In the previous work on the antimycobacterial activity of TxHxE, the active compounds responsible for the biological activity were not identified. In that study, flavone 2 was identified in an active fraction of TxHxE, but the isolated compound lacked antimycobacterial activity. However, the antimycobacterial activity of the TxHxE active fraction was improved after enrichment with 2, suggesting a synergistic effect between different compounds of T. angustifolia [23]. To our knowledge, we report the antimycobacterial activity of trixanolides for the first time, expanding the previously reported spectrum of sesquiterpene derivatives isolated from plants against microbial pathogens [49]. This family of compounds is characteristic of the Trixis genus and has been the subject of several studies in different species [22,26,28–32]. Further investigations are needed to identify the structural components of trixanolides related to their activity against infectious agents and to propose them as the structural basis for developing new antimicrobial drugs.

Acute toxicity of TxAcE

The acute toxicity results showed that neither mortality nor toxic signs were observed in animals after the TxAcE was administered at a dose of 2000 mg/kg. Additionally, no significant gross pathological changes were observed in vital organs. These results suggest that the LD₅₀ of the TxAcE examined in the present study is greater than 2000 mg/kg and can be classified in class 5 according to the OECD 423 guidelines [38].

TxAcE improves glucose and lipid profiles in diabetic mice

DM is a medical condition characterized by hyperglycemia, defects in insulin secretion, insulin action, or both, and is associated with abnormalities in carbohydrate, protein, and lipid metabolism [50]. DM remains one of the deadliest non-communicable diseases worldwide, with an estimated mortality of 3.4 million people in 2024 [1]. Despite advances in modern medicine, medicinal plants and their derivatives are still promising options for improving treatment for diabetic patients [51]. Our previous in vivo study showed that an aqueous extract of T. angustifolia has hypoglycemic and hypolipidemic effects in alloxan-induced diabetic mice, and we found that flavone 2 is also present in the ethyl acetate fraction derived from this extract [24,25]. Motivated by these outcomes, we decided to investigate the hypoglycemic effect of TxAcE in this model. Alloxan is used as a hyperglycemic-inducing agent in experimental animals due to its selective pancreatic islet β-cell cytotoxicity, leading to hyperglycemia and diabetic complications [52]. In this study, intraperitoneal administration of alloxan to mice significantly increased blood glucose levels five days after injection. This increase persisted and progressed until the end of the experimental period (Fig 3, S1 File). However, daily treatment with TxAcE (200 mg/kg) for 15 days gradually reduced non-fasting blood glucose from 415.86 ± 23.4 mg/dL to 288.14 ± 50.8 mg/dL compared to the alloxan-induced diabetes group (523.57 ± 29.3 mg/dL). The hypoglycemic effect was observed from the 9^th day to the end of the study (15^th day), with a marked blood glucose reduction of 35.21% (p ≤ 0.05) and 44.97% (p ≤ 0.05), respectively. This reduction observed at the 15th day was even lower than the previous reduction reported (30.4%) when 100 mg/kg of the aqueous extract of T. angustifolia was administered in a similar time lapse experiment [25]. Treatment with a lower dose of TxAcE (50 mg/kg) in hyperglycemic mice lowered blood glucose levels on the 11^th day (−31.07%), but this effect was not observed until the end of the study (−19.29%). This result could be explained by the dose-response phenomenon called hormesis, which results from several factors, such as the action of a complex mixture of bioactive constituents or interactions among these compounds [53,54]

Download:

Fig 3. Effect of the ethyl acetate extract of Trixis angustifolia DC. (TxAcE) on blood glucose levels in alloxan-induced diabetic mice after 15 days of treatment.

Data are expressed as mean ± SEM with n = 7. *p < 0.05 compared to the diabetic group. D: Diabetic.

https://doi.org/10.1371/journal.pone.0339176.g003

DM is associated with abnormal blood lipid metabolism, which includes elevated fasting plasma triglycerides (TG) levels, small dense low-density lipoprotein-cholesterol, and low levels of high-density lipoprotein cholesterol (HDL-C) [55]. These factors increase the risk of heart disease. Alloxan-induced diabetic mice showed a significant increase in low-density lipoprotein-cholesterol (LDL-C) levels, while HDL-C levels were significantly decreased compared to normal control mice (Table 3). The treatment with TxAcE (200 mg/kg) induced a significant reduction in LDL-C (−64.28%) and an increase in HDL-C (40.07%) levels compared with the alloxan-induced diabetic group, suggesting that the extract can improve the alloxan-induced perturbations of serum lipids in diabetic mice. The improvement of glycemia could mediate this effect, observed at a 200 mg/kg extract dose. Thus, these results indicated that T. angustifolia could help improve dyslipidemia and prevent certain diabetic complications.

Download:

Table 3. Effect of the ethyl acetate extract of Trixis angustifolia DC. (TxAcE) on lipid profile of alloxan-induced diabetic mice.

https://doi.org/10.1371/journal.pone.0339176.t003

Effect of TxAcE on Triton WR-1339-induced hyperlipidemia

Dyslipidemia is common among people living with type 2 diabetes and is considered a major risk factor for cardiovascular disease. Lipid-lowering drugs are important for improving diabetic complications [56]. Therefore, the lipid-lowering activity of TxAcE was also investigated in Triton WR-1339-induced hyperlipidemia in mice. Triton WR-1339 prevents TG catabolism by inhibiting lipoprotein lipase activity, blocking the uptake of TG-rich lipoproteins from the circulation [57,58]. In this study, Triton WR-1339 (400 mg/kg) caused a significant elevation in serum levels of TG (55.23%), Very-low-density lipoprotein cholesterol (VLDL-C) (55.25%), and LDL-C (73.99%), and a marked decrease in HDL-C level (−68.37%) compared to the normal group (Table 4). After treatment with 50, 100, and 200 mg/kg of the TxAcE, a significant reduction in TG and VLDL-C levels was observed compared to the hyperlipidemic group. Additionally, serum levels of LDL-C decreased significantly at all doses (Table 4).

Download:

Table 4. Effect of the ethyl acetate extract of Trixis angustifolia DC. (TxAcE) on Triton WR-1339-Induced Hyperlipidemia.

https://doi.org/10.1371/journal.pone.0339176.t004

In contrast, HDL-C levels increased significantly at 50 and 100 mg/kg doses. According to a previously proposed role for HDL-C [59], the increased levels of HDL-C observed after the administration of TxAcE could contribute to cholesterol removal from peripheral tissues, resulting in the decreased levels of LDL-C observed in serum. This reduction is promising since LDL-C levels constitute the main modifiable risk factor for cardiovascular disease [60]. These observations are similar to our previous results showing a decrease of TG and VLDL-C and an increase of HDL-C in Triton WR-1339-induced hyperlipidemic mice after treatment with the aqueous extract of T. angustifolia [24]. Therefore, compounds with this effect could be extracted using water or ethyl acetate.

Conclusion

Plants used in traditional medicine offer a promising source of molecules with potential applications in health care. Mexico has a high diversity of medicinal plants; among them, T. angustifolia is used by the Mexican population to treat different diseases. Here, we demonstrate that an ethyl acetate extract from T. angustifolia and a mixture of two new trixanolides (1a and 1a’) isolated exhibited significant antimycobacterial activity. Furthermore, the effectiveness of this extract in reducing blood glucose and LDL-C in diabetic mice suggests its potential value for future research in co-managing both diabetes mellitus and tuberculosis. This study also contributes to the pharmacological characterization of this plant and supports its use in Mexican traditional medicine.

Supporting information

S1 Fig. ¹H NMR spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

https://doi.org/10.1371/journal.pone.0339176.s001

(PDF)

S2a Fig. ¹³C NMR spectrum of mixture of 1a and 1a’ (125 MHz, CDC_l3).

https://doi.org/10.1371/journal.pone.0339176.s002

(PDF)

S2b Fig. ¹³C NMR spectrum of mixture of 1a and 1a’ (125 MHz, CDCl3).

https://doi.org/10.1371/journal.pone.0339176.s003

(PDF)

S3 Fig. COSY spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

https://doi.org/10.1371/journal.pone.0339176.s004

(PDF)

S4 Fig. TOCSY spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

https://doi.org/10.1371/journal.pone.0339176.s005

(PDF)

S5a Fig. HSQC spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

https://doi.org/10.1371/journal.pone.0339176.s006

(PDF)

S5b Fig. HSQC spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

https://doi.org/10.1371/journal.pone.0339176.s007

(PDF)

S6a Fig. HMBC spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

https://doi.org/10.1371/journal.pone.0339176.s008

(PDF)

S6b Fig. HMBC spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

https://doi.org/10.1371/journal.pone.0339176.s009

(PDF)

S6c Fig. HMBC spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

https://doi.org/10.1371/journal.pone.0339176.s010

(PDF)

S7 Fig. ROESY spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

https://doi.org/10.1371/journal.pone.0339176.s011

(PDF)

S8 Fig. HRMS-ESI spectrum (positive ion mode) of mixture of 1a and 1a’.

https://doi.org/10.1371/journal.pone.0339176.s012

(PDF)

S1 File. Values behind the means used to build graphs and tables.

https://doi.org/10.1371/journal.pone.0339176.s013

(XLSX)

Acknowledgments

The authors thank the Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional (SIP-IPN). AS-G, FUR-R, OM-P, LC-G, JL-H, and MEV-D thank the SECIHTI program Sistema Nacional de Investigadoras e Investigadores (SNII).

References

1. International Diabetes Federation. IDF diabetes atlas. 11 ed. Brussels, Belgium: International Diabetes Federation. 2022.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81–90. pmid:24357215
- View Article
- PubMed/NCBI
- Google Scholar
3. Toniolo A, Cassani G, Puggioni A, Rossi A, Colombo A, Onodera T, et al. The diabetes pandemic and associated infections: suggestions for clinical microbiology. Rev Med Microbiol. 2019;30(1):1–17. pmid:30662163
- View Article
- PubMed/NCBI
- Google Scholar
4. Ferlita S, Yegiazaryan A, Noori N, Lal G, Nguyen T, To K, et al. Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis. J Clin Med. 2019;8(12):2219. pmid:31888124
- View Article
- PubMed/NCBI
- Google Scholar
5. Global tuberculosis report 2023. Geneva: World Health Organization. 2023.
6. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737–46. pmid:19926034
- View Article
- PubMed/NCBI
- Google Scholar
7. Riza AL, Pearson F, Ugarte-Gil C, Alisjahbana B, van de Vijver S, Panduru NM, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014;2(9):740–53. pmid:25194887
- View Article
- PubMed/NCBI
- Google Scholar
8. Green E, Samie A, Obi CL, Bessong PO, Ndip RN. Inhibitory properties of selected South African medicinal plants against Mycobacterium tuberculosis. J Ethnopharmacol. 2010;130(1):151–7. pmid:20447452
- View Article
- PubMed/NCBI
- Google Scholar
9. Maroyi A. Ethnopharmacology and Therapeutic Value of Bridelia micrantha (Hochst.) Baill. in Tropical Africa: A Comprehensive Review. Molecules. 2017;22(9):1493. pmid:28885590
- View Article
- PubMed/NCBI
- Google Scholar
10. Abdel-Hassan IA, Abdel-Barry JA, Tariq Mohammeda S. The hypoglycaemic and antihyperglycaemic effect of citrullus colocynthis fruit aqueous extract in normal and alloxan diabetic rabbits. J Ethnopharmacol. 2000;71(1–2):325–30. pmid:10904181
- View Article
- PubMed/NCBI
- Google Scholar
11. Mehta A, Srivastva G, Kachhwaha S, Sharma M, Kothari SL. Antimycobacterial activity of Citrullus colocynthis (L.) Schrad. against drug sensitive and drug resistant Mycobacterium tuberculosis and MOTT clinical isolates. J Ethnopharmacol. 2013;149(1):195–200. pmid:23816500
- View Article
- PubMed/NCBI
- Google Scholar
12. POWO. Plants of the World Online. https://powo.science.kew.org. 2025. Accessed 2025 June 17.
- View Article
- Google Scholar
13. Keil DJ. Trixis. In: Flora of North America Editorial Committee, editor. Flora of North America North of Mexico. New York: Oxford University Press. 2006:75–6.
14. Villaseñor JL. Checklist of the native vascular plants of México. RevMexBiodiv. 2016;87(3).
- View Article
- Google Scholar
15. Villaseñor JL. Diversidad y distribución de la familia Asteraceae en México. Bot Sci. 2018;96(2):332–58.
- View Article
- Google Scholar
16. Hirschhorn HH. Botanical remedies of South and Central America, and the Caribbean: an archival analysis. Part I. J Ethnopharmacol. 1981;4(2):129–58. pmid:7311595
- View Article
- PubMed/NCBI
- Google Scholar
17. Alarcon-Aguilar FJ, Roman-Ramos R. Antidiabetic plants in Mexico and Central America. In: Soumyanath A, editor. Traditional medicines for modern times: antidiabetic plants. Boca Raton (FL): CRC Press, Taylor & Francis. 2005:221–4.
18. Rocha-Gracia RC, Hernández Arroyo MM, Lozano Zaraín P, Hernández Carlos B, Santiago Romero H, Cedillo Portugal E. Antibacterial activity of crude extracts from Mexican plants against methicillin-resistant Staphylococcus. Afr J Biotechnol. 2011;10(61):13202–18.
- View Article
- Google Scholar
19. Estrada-Castillón E, Soto-Mata BE, Garza-López M, Villarreal-Quintanilla JÁ, Jiménez-Pérez J, Pando-Moreno M, et al. Medicinal plants in the southern region of the State of Nuevo León, México. J Ethnobiol Ethnomed. 2012;8:45. pmid:23231862
- View Article
- PubMed/NCBI
- Google Scholar
20. Ribeiro A, Piló-Veloso D, Romanha AJ, Zani CL. Trypanocidal flavonoids from Trixis vauthieri. J Nat Prod. 1997;60(8):836–41. pmid:9287419
- View Article
- PubMed/NCBI
- Google Scholar
21. Pereira FH, Guimaraes LDA, Cerutti SM, Rodrigues RFDO, Araujo CEP. Preliminary anti-ulcerogenic and chemical analysis of the aerial parts of Trixis divaricata Sprengel. Acta Farm Bonaerense. 2005;24(1):80–4.
- View Article
- Google Scholar
22. Maldonado EM, Salamanca E, Giménez A, Saavedra G, Sterner O. Antileishmanial metabolites from Trixis antimenorrhoea. Phytochemistry Letters. 2014;10:281–6.
- View Article
- Google Scholar
23. Sánchez-Chávez AC, Salazar-Gómez A, Zepeda-Vallejo LG, Hernández deJesús MDL, Quintos-Escalante M, Vargas-Díaz ME, et al. Trixis angustifolia hexanic extract displays synergistic antibacterial activity against M. tuberculosis. Nat. Prod. Res. 2019;33(10): 1477–81.
- View Article
- Google Scholar
24. Salazar-Gómez A, Sánchez-Chávez AC, Zepeda-Vallejo G, Chamorro-Cevallos G, Garduño-Siciliano L, Vargas-Díaz E. Hypolipidemic Effect of Trixis angustifolia Aqueous Extract on Triton WR-1339- and High-Fat Diet-Induced Hyperlipidemic Mice. Natural Product Communications. 2019;14(7).
- View Article
- Google Scholar
25. Salazar-Gómez A, Vargas-Díaz ME, Garduño-Siciliano L. Hypoglycemic potential of Trixis angustifolia aqueous extract in alloxan-induced diabetic mice. Bangladesh J Pharmacol. 2019;14(2):74–9.
- View Article
- Google Scholar
26. Sales Junior PA, Zani CL, de Siqueira EP, Kohlhoff M, Marques FR, Caldeira ASP, et al. Trypanocidal Trixikingolides From Trixis Vauthieri. Nat Prod Res. 2021;35(16):2691–9. pmid:31530021
- View Article
- PubMed/NCBI
- Google Scholar
27. Salazar-Gómez A, Vargas-Díaz ME, Meléndez-Camargo ME, Pablo-Pérez SS. Antinociceptive activity of the ethanolic extract of Trixis angustifolia DC. Nat Prod Res. 2022;36(22):5813–6. pmid:34963401
- View Article
- PubMed/NCBI
- Google Scholar
28. Bohlmann F, Zdero C. Natürlich vorkommende Terpen‐Derivate, 156. Über eine neue Gruppe von Sesquiterpenlactonen aus der Gattung Trixis. Chem Ber. 1979;112(2):435–44.
- View Article
- Google Scholar
29. Bohlmann F, Suwita A, Jakupovic J, King RM, Robinson H. Trixikingolides and germacrene derivatives from Trixis species. Phytochemistry. 1981;20(7):1649–55.
- View Article
- Google Scholar
30. De Riscala EC, Catalan CAN, Sosa VE, Gutiérrez AB, Herz W. Trixane derivatives from Trixis praestans. Phytochemistry. 1988;27(7):2343–6.
- View Article
- Google Scholar
31. de Riscala EC, Catalán CAN, Legname PR, Gutiérrez AB, Herz W. Trixanolide and germacratriene derivatives from Trixis grisebachii. Phytochemistry. 1989;28(8):2155–61.
- View Article
- Google Scholar
32. Kotowicz C, Hernández LR, Cerda-García-Rojas CM, Villecco MB, Catalán CA, Joseph-Nathan P. Absolute configuration of trixanolides from Trixis pallida. J Nat Prod. 2001;64(10):1326–31. pmid:11678660
- View Article
- PubMed/NCBI
- Google Scholar
33. García RG. Plantas medicinales de Aguascalientes. Aguascalientes (México): Universidad Autónoma de Aguascalientes. 2015.
34. González-Elizondo M, López-Enriquez IL, González-Elizondo MS, Tena-Flores JA. Plantas Medicinales del Estado de Durango y Zonas Aledañas. México: Instituto Politécnico Nacional, Centro Interdisciplinario de Investigación para el Desarrollo Integral Regional Unidad Durango. 2004.
35. Rodríguez-Chávez JL, Egas V, Linares E, Bye R, Hernández T, Espinosa-García FJ, et al. Mexican Arnica (Heterotheca inuloides Cass. Asteraceae: Astereae): Ethnomedical uses, chemical constituents and biological properties. J Ethnopharmacol. 2017;195:39–63. pmid:27847336
- View Article
- PubMed/NCBI
- Google Scholar
36. Secretaría de Agricultura, Ganadería, Desarrollo Rural, Pesca y Alimentación (SAGARPA). NOM-062-ZOO-1999. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio. México: SAGARPA. 2001.
37. Jimenez-Arellanes A, Meckes M, Ramirez R, Torres J, Luna-Herrera J. Activity against multidrug-resistant Mycobacterium tuberculosis in Mexican plants used to treat respiratory diseases. Phytother Res. 2003;17(8):903–8. pmid:13680821
- View Article
- PubMed/NCBI
- Google Scholar
38. Organisation for Economic Co-operation and Development OECD. Guidelines for the testing of chemicals. Paris: OECD. 2001.
39. Issa IA, Hussen Bule M. Hypoglycemic Effect of Aqueous and Methanolic Extract of Artemisia afra on Alloxan Induced Diabetic Swiss Albino Mice. Evid Based Complement Alternat Med. 2015;2015:752486. pmid:26345313
- View Article
- PubMed/NCBI
- Google Scholar
40. Mendieta A, Jiménez F, Garduño-Siciliano L, Mojica-Villegas A, Rosales-Acosta B, Villa-Tanaca L, et al. Synthesis and highly potent hypolipidemic activity of alpha-asarone- and fibrate-based 2-acyl and 2-alkyl phenols as HMG-CoA reductase inhibitors. Bioorg Med Chem. 2014;22(21):5871–82. pmid:25311563
- View Article
- PubMed/NCBI
- Google Scholar
41. Argüelles N, Sánchez-Sandoval E, Mendieta A, Villa-Tanaca L, Garduño-Siciliano L, Jiménez F, et al. Design, synthesis, and docking of highly hypolipidemic agents: Schizosaccharomyces pombe as a new model for evaluating alpha-asarone-based HMG-CoA reductase inhibitors. Bioorg Med Chem. 2010;18(12):4238–48. pmid:20576575
- View Article
- PubMed/NCBI
- Google Scholar
42. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clinical Chemistry. 1972;18(6):499–502.
- View Article
- Google Scholar
43. Ntutela S, Smith P, Matika L, Mukinda J, Arendse H, Allie N, et al. Efficacy of Artemisia afra phytotherapy in experimental tuberculosis. Tuberculosis (Edinb). 2009;89 Suppl 1(Suppl 1):S33–40. pmid:20006302
- View Article
- PubMed/NCBI
- Google Scholar
44. Robles-Zepeda RE, Coronado-Aceves EW, Velázquez-Contreras CA, Ruiz-Bustos E, Navarro-Navarro M, Garibay-Escobar A. In vitro anti-mycobacterial activity of nine medicinal plants used by ethnic groups in Sonora, Mexico. BMC Complement Altern Med. 2013;13:329. pmid:24267469
- View Article
- PubMed/NCBI
- Google Scholar
45. Hernández-Sánchez KM, Garduño-Siciliano L, Luna-Herrera J, Zepeda-Vallejo LG, Lagunas-Rivera S, García-Gutiérrez GE, et al. Antimycobacterial and hypolipemiant activities of Bidens odorata (Cavanilles). J Ethnopharmacol. 2018;222:159–64. pmid:29704591
- View Article
- PubMed/NCBI
- Google Scholar
46. Johansen MD, Herrmann J-L, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020;18(7):392–407. pmid:32086501
- View Article
- PubMed/NCBI
- Google Scholar
47. Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol. 2020;11:303. pmid:32194556
- View Article
- PubMed/NCBI
- Google Scholar
48. Kam JY, Hortle E, Krogman E, Warner SE, Wright K, Luo K, et al. Rough and smooth variants of Mycobacterium abscessus are differentially controlled by host immunity during chronic infection of adult zebrafish. Nat Commun. 2022;13(1):952. pmid:35177649
- View Article
- PubMed/NCBI
- Google Scholar
49. Santhosh RS, Suriyanarayanan B. Plants: a source for new antimycobacterial drugs. Planta Med. 2014;80(1):9–21. pmid:24218370
- View Article
- PubMed/NCBI
- Google Scholar
50. World Health Organization. Classification of diabetes mellitus. Geneva: World Health Organization. 2019.
51. Salmerón-Manzano E, Garrido-Cardenas JA, Manzano-Agugliaro F. Worldwide Research Trends on Medicinal Plants. Int J Environ Res Public Health. 2020;17(10):3376. pmid:32408690
- View Article
- PubMed/NCBI
- Google Scholar
52. Ighodaro OM, Adeosun AM, Akinloye OA. Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies. Medicina (Kaunas). 2017;53(6):365–74. pmid:29548636
- View Article
- PubMed/NCBI
- Google Scholar
53. Calabrese EJ, Baldwin LA. Hormesis: U-shaped dose responses and their centrality in toxicology. Trends Pharmacol Sci. 2001;22(6):285–91. pmid:11395156
- View Article
- PubMed/NCBI
- Google Scholar
54. Jodynis-Liebert J, Kujawska M. Biphasic Dose-Response Induced by Phytochemicals: Experimental Evidence. J Clin Med. 2020;9(3):718. pmid:32155852
- View Article
- PubMed/NCBI
- Google Scholar
55. Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, et al. Diabetes and lipid metabolism. Hormones (Athens). 2018;17(1):61–7. pmid:29858856
- View Article
- PubMed/NCBI
- Google Scholar
56. Jialal I, Singh G. Management of diabetic dyslipidemia: An update. World J Diabetes. 2019;10(5):280–90. pmid:31139315
- View Article
- PubMed/NCBI
- Google Scholar
57. Schotz MC, Scanu A, Page IH. Effect of triton on lipoprotein lipase of rat plasma. Am J Physiol. 1957;188(2):399–402. pmid:13411223
- View Article
- PubMed/NCBI
- Google Scholar
58. Millar JS, Cromley DA, McCoy MG, Rader DJ, Billheimer JT. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res. 2005;46(9):2023–8. pmid:15995182
- View Article
- PubMed/NCBI
- Google Scholar
59. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50 Suppl(Suppl):S189–94. pmid:19064999
- View Article
- PubMed/NCBI
- Google Scholar
60. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285–350.
- View Article
- Google Scholar

[ref1] 1. International Diabetes Federation. IDF diabetes atlas. 11 ed. Brussels, Belgium: International Diabetes Federation. 2022.

[ref2] 2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81–90. pmid:24357215
View Article
PubMed/NCBI
Google Scholar

[3] View Article

[4] PubMed/NCBI

[5] Google Scholar

[ref3] 3. Toniolo A, Cassani G, Puggioni A, Rossi A, Colombo A, Onodera T, et al. The diabetes pandemic and associated infections: suggestions for clinical microbiology. Rev Med Microbiol. 2019;30(1):1–17. pmid:30662163
View Article
PubMed/NCBI
Google Scholar

[7] View Article

[8] PubMed/NCBI

[9] Google Scholar

[ref4] 4. Ferlita S, Yegiazaryan A, Noori N, Lal G, Nguyen T, To K, et al. Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis. J Clin Med. 2019;8(12):2219. pmid:31888124
View Article
PubMed/NCBI
Google Scholar

[11] View Article

[12] PubMed/NCBI

[13] Google Scholar

[ref5] 5. Global tuberculosis report 2023. Geneva: World Health Organization. 2023.

[ref6] 6. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737–46. pmid:19926034
View Article
PubMed/NCBI
Google Scholar

[16] View Article

[17] PubMed/NCBI

[18] Google Scholar

[ref7] 7. Riza AL, Pearson F, Ugarte-Gil C, Alisjahbana B, van de Vijver S, Panduru NM, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014;2(9):740–53. pmid:25194887
View Article
PubMed/NCBI
Google Scholar

[20] View Article

[21] PubMed/NCBI

[22] Google Scholar

[ref8] 8. Green E, Samie A, Obi CL, Bessong PO, Ndip RN. Inhibitory properties of selected South African medicinal plants against Mycobacterium tuberculosis. J Ethnopharmacol. 2010;130(1):151–7. pmid:20447452
View Article
PubMed/NCBI
Google Scholar

[24] View Article

[25] PubMed/NCBI

[26] Google Scholar

[ref9] 9. Maroyi A. Ethnopharmacology and Therapeutic Value of Bridelia micrantha (Hochst.) Baill. in Tropical Africa: A Comprehensive Review. Molecules. 2017;22(9):1493. pmid:28885590
View Article
PubMed/NCBI
Google Scholar

[28] View Article

[29] PubMed/NCBI

[30] Google Scholar

[ref10] 10. Abdel-Hassan IA, Abdel-Barry JA, Tariq Mohammeda S. The hypoglycaemic and antihyperglycaemic effect of citrullus colocynthis fruit aqueous extract in normal and alloxan diabetic rabbits. J Ethnopharmacol. 2000;71(1–2):325–30. pmid:10904181
View Article
PubMed/NCBI
Google Scholar

[32] View Article

[33] PubMed/NCBI

[34] Google Scholar

[ref11] 11. Mehta A, Srivastva G, Kachhwaha S, Sharma M, Kothari SL. Antimycobacterial activity of Citrullus colocynthis (L.) Schrad. against drug sensitive and drug resistant Mycobacterium tuberculosis and MOTT clinical isolates. J Ethnopharmacol. 2013;149(1):195–200. pmid:23816500
View Article
PubMed/NCBI
Google Scholar

[36] View Article

[37] PubMed/NCBI

[38] Google Scholar

[ref12] 12. POWO. Plants of the World Online. https://powo.science.kew.org. 2025. Accessed 2025 June 17.
View Article
Google Scholar

[40] View Article

[41] Google Scholar

[ref13] 13. Keil DJ. Trixis. In: Flora of North America Editorial Committee, editor. Flora of North America North of Mexico. New York: Oxford University Press. 2006:75–6.

[ref14] 14. Villaseñor JL. Checklist of the native vascular plants of México. RevMexBiodiv. 2016;87(3).
View Article
Google Scholar

[44] View Article

[45] Google Scholar

[ref15] 15. Villaseñor JL. Diversidad y distribución de la familia Asteraceae en México. Bot Sci. 2018;96(2):332–58.
View Article
Google Scholar

[47] View Article

[48] Google Scholar

[ref16] 16. Hirschhorn HH. Botanical remedies of South and Central America, and the Caribbean: an archival analysis. Part I. J Ethnopharmacol. 1981;4(2):129–58. pmid:7311595
View Article
PubMed/NCBI
Google Scholar

[50] View Article

[51] PubMed/NCBI

[52] Google Scholar

[ref17] 17. Alarcon-Aguilar FJ, Roman-Ramos R. Antidiabetic plants in Mexico and Central America. In: Soumyanath A, editor. Traditional medicines for modern times: antidiabetic plants. Boca Raton (FL): CRC Press, Taylor & Francis. 2005:221–4.

[ref18] 18. Rocha-Gracia RC, Hernández Arroyo MM, Lozano Zaraín P, Hernández Carlos B, Santiago Romero H, Cedillo Portugal E. Antibacterial activity of crude extracts from Mexican plants against methicillin-resistant Staphylococcus. Afr J Biotechnol. 2011;10(61):13202–18.
View Article
Google Scholar

[55] View Article

[56] Google Scholar

[ref19] 19. Estrada-Castillón E, Soto-Mata BE, Garza-López M, Villarreal-Quintanilla JÁ, Jiménez-Pérez J, Pando-Moreno M, et al. Medicinal plants in the southern region of the State of Nuevo León, México. J Ethnobiol Ethnomed. 2012;8:45. pmid:23231862
View Article
PubMed/NCBI
Google Scholar

[58] View Article

[59] PubMed/NCBI

[60] Google Scholar

[ref20] 20. Ribeiro A, Piló-Veloso D, Romanha AJ, Zani CL. Trypanocidal flavonoids from Trixis vauthieri. J Nat Prod. 1997;60(8):836–41. pmid:9287419
View Article
PubMed/NCBI
Google Scholar

[62] View Article

[63] PubMed/NCBI

[64] Google Scholar

[ref21] 21. Pereira FH, Guimaraes LDA, Cerutti SM, Rodrigues RFDO, Araujo CEP. Preliminary anti-ulcerogenic and chemical analysis of the aerial parts of Trixis divaricata Sprengel. Acta Farm Bonaerense. 2005;24(1):80–4.
View Article
Google Scholar

[66] View Article

[67] Google Scholar

[ref22] 22. Maldonado EM, Salamanca E, Giménez A, Saavedra G, Sterner O. Antileishmanial metabolites from Trixis antimenorrhoea. Phytochemistry Letters. 2014;10:281–6.
View Article
Google Scholar

[69] View Article

[70] Google Scholar

[ref23] 23. Sánchez-Chávez AC, Salazar-Gómez A, Zepeda-Vallejo LG, Hernández deJesús MDL, Quintos-Escalante M, Vargas-Díaz ME, et al. Trixis angustifolia hexanic extract displays synergistic antibacterial activity against M. tuberculosis. Nat. Prod. Res. 2019;33(10): 1477–81.
View Article
Google Scholar

[72] View Article

[73] Google Scholar

[ref24] 24. Salazar-Gómez A, Sánchez-Chávez AC, Zepeda-Vallejo G, Chamorro-Cevallos G, Garduño-Siciliano L, Vargas-Díaz E. Hypolipidemic Effect of Trixis angustifolia Aqueous Extract on Triton WR-1339- and High-Fat Diet-Induced Hyperlipidemic Mice. Natural Product Communications. 2019;14(7).
View Article
Google Scholar

[75] View Article

[76] Google Scholar

[ref25] 25. Salazar-Gómez A, Vargas-Díaz ME, Garduño-Siciliano L. Hypoglycemic potential of Trixis angustifolia aqueous extract in alloxan-induced diabetic mice. Bangladesh J Pharmacol. 2019;14(2):74–9.
View Article
Google Scholar

[78] View Article

[79] Google Scholar

[ref26] 26. Sales Junior PA, Zani CL, de Siqueira EP, Kohlhoff M, Marques FR, Caldeira ASP, et al. Trypanocidal Trixikingolides From Trixis Vauthieri. Nat Prod Res. 2021;35(16):2691–9. pmid:31530021
View Article
PubMed/NCBI
Google Scholar

[81] View Article

[82] PubMed/NCBI

[83] Google Scholar

[ref27] 27. Salazar-Gómez A, Vargas-Díaz ME, Meléndez-Camargo ME, Pablo-Pérez SS. Antinociceptive activity of the ethanolic extract of Trixis angustifolia DC. Nat Prod Res. 2022;36(22):5813–6. pmid:34963401
View Article
PubMed/NCBI
Google Scholar

[85] View Article

[86] PubMed/NCBI

[87] Google Scholar

[ref28] 28. Bohlmann F, Zdero C. Natürlich vorkommende Terpen‐Derivate, 156. Über eine neue Gruppe von Sesquiterpenlactonen aus der Gattung Trixis. Chem Ber. 1979;112(2):435–44.
View Article
Google Scholar

[89] View Article

[90] Google Scholar

[ref29] 29. Bohlmann F, Suwita A, Jakupovic J, King RM, Robinson H. Trixikingolides and germacrene derivatives from Trixis species. Phytochemistry. 1981;20(7):1649–55.
View Article
Google Scholar

[92] View Article

[93] Google Scholar

[ref30] 30. De Riscala EC, Catalan CAN, Sosa VE, Gutiérrez AB, Herz W. Trixane derivatives from Trixis praestans. Phytochemistry. 1988;27(7):2343–6.
View Article
Google Scholar

[95] View Article

[96] Google Scholar

[ref31] 31. de Riscala EC, Catalán CAN, Legname PR, Gutiérrez AB, Herz W. Trixanolide and germacratriene derivatives from Trixis grisebachii. Phytochemistry. 1989;28(8):2155–61.
View Article
Google Scholar

[98] View Article

[99] Google Scholar

[ref32] 32. Kotowicz C, Hernández LR, Cerda-García-Rojas CM, Villecco MB, Catalán CA, Joseph-Nathan P. Absolute configuration of trixanolides from Trixis pallida. J Nat Prod. 2001;64(10):1326–31. pmid:11678660
View Article
PubMed/NCBI
Google Scholar

[101] View Article

[102] PubMed/NCBI

[103] Google Scholar

[ref33] 33. García RG. Plantas medicinales de Aguascalientes. Aguascalientes (México): Universidad Autónoma de Aguascalientes. 2015.

[ref34] 34. González-Elizondo M, López-Enriquez IL, González-Elizondo MS, Tena-Flores JA. Plantas Medicinales del Estado de Durango y Zonas Aledañas. México: Instituto Politécnico Nacional, Centro Interdisciplinario de Investigación para el Desarrollo Integral Regional Unidad Durango. 2004.

[ref35] 35. Rodríguez-Chávez JL, Egas V, Linares E, Bye R, Hernández T, Espinosa-García FJ, et al. Mexican Arnica (Heterotheca inuloides Cass. Asteraceae: Astereae): Ethnomedical uses, chemical constituents and biological properties. J Ethnopharmacol. 2017;195:39–63. pmid:27847336
View Article
PubMed/NCBI
Google Scholar

[107] View Article

[108] PubMed/NCBI

[109] Google Scholar

[ref36] 36. Secretaría de Agricultura, Ganadería, Desarrollo Rural, Pesca y Alimentación (SAGARPA). NOM-062-ZOO-1999. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio. México: SAGARPA. 2001.

[ref37] 37. Jimenez-Arellanes A, Meckes M, Ramirez R, Torres J, Luna-Herrera J. Activity against multidrug-resistant Mycobacterium tuberculosis in Mexican plants used to treat respiratory diseases. Phytother Res. 2003;17(8):903–8. pmid:13680821
View Article
PubMed/NCBI
Google Scholar

[112] View Article

[113] PubMed/NCBI

[114] Google Scholar

[ref38] 38. Organisation for Economic Co-operation and Development OECD. Guidelines for the testing of chemicals. Paris: OECD. 2001.

[ref39] 39. Issa IA, Hussen Bule M. Hypoglycemic Effect of Aqueous and Methanolic Extract of Artemisia afra on Alloxan Induced Diabetic Swiss Albino Mice. Evid Based Complement Alternat Med. 2015;2015:752486. pmid:26345313
View Article
PubMed/NCBI
Google Scholar

[117] View Article

[118] PubMed/NCBI

[119] Google Scholar

[ref40] 40. Mendieta A, Jiménez F, Garduño-Siciliano L, Mojica-Villegas A, Rosales-Acosta B, Villa-Tanaca L, et al. Synthesis and highly potent hypolipidemic activity of alpha-asarone- and fibrate-based 2-acyl and 2-alkyl phenols as HMG-CoA reductase inhibitors. Bioorg Med Chem. 2014;22(21):5871–82. pmid:25311563
View Article
PubMed/NCBI
Google Scholar

[121] View Article

[122] PubMed/NCBI

[123] Google Scholar

[ref41] 41. Argüelles N, Sánchez-Sandoval E, Mendieta A, Villa-Tanaca L, Garduño-Siciliano L, Jiménez F, et al. Design, synthesis, and docking of highly hypolipidemic agents: Schizosaccharomyces pombe as a new model for evaluating alpha-asarone-based HMG-CoA reductase inhibitors. Bioorg Med Chem. 2010;18(12):4238–48. pmid:20576575
View Article
PubMed/NCBI
Google Scholar

[125] View Article

[126] PubMed/NCBI

[127] Google Scholar

[ref42] 42. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clinical Chemistry. 1972;18(6):499–502.
View Article
Google Scholar

[129] View Article

[130] Google Scholar

[ref43] 43. Ntutela S, Smith P, Matika L, Mukinda J, Arendse H, Allie N, et al. Efficacy of Artemisia afra phytotherapy in experimental tuberculosis. Tuberculosis (Edinb). 2009;89 Suppl 1(Suppl 1):S33–40. pmid:20006302
View Article
PubMed/NCBI
Google Scholar

[132] View Article

[133] PubMed/NCBI

[134] Google Scholar

[ref44] 44. Robles-Zepeda RE, Coronado-Aceves EW, Velázquez-Contreras CA, Ruiz-Bustos E, Navarro-Navarro M, Garibay-Escobar A. In vitro anti-mycobacterial activity of nine medicinal plants used by ethnic groups in Sonora, Mexico. BMC Complement Altern Med. 2013;13:329. pmid:24267469
View Article
PubMed/NCBI
Google Scholar

[136] View Article

[137] PubMed/NCBI

[138] Google Scholar

[ref45] 45. Hernández-Sánchez KM, Garduño-Siciliano L, Luna-Herrera J, Zepeda-Vallejo LG, Lagunas-Rivera S, García-Gutiérrez GE, et al. Antimycobacterial and hypolipemiant activities of Bidens odorata (Cavanilles). J Ethnopharmacol. 2018;222:159–64. pmid:29704591
View Article
PubMed/NCBI
Google Scholar

[140] View Article

[141] PubMed/NCBI

[142] Google Scholar

[ref46] 46. Johansen MD, Herrmann J-L, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020;18(7):392–407. pmid:32086501
View Article
PubMed/NCBI
Google Scholar

[144] View Article

[145] PubMed/NCBI

[146] Google Scholar

[ref47] 47. Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol. 2020;11:303. pmid:32194556
View Article
PubMed/NCBI
Google Scholar

[148] View Article

[149] PubMed/NCBI

[150] Google Scholar

[ref48] 48. Kam JY, Hortle E, Krogman E, Warner SE, Wright K, Luo K, et al. Rough and smooth variants of Mycobacterium abscessus are differentially controlled by host immunity during chronic infection of adult zebrafish. Nat Commun. 2022;13(1):952. pmid:35177649
View Article
PubMed/NCBI
Google Scholar

[152] View Article

[153] PubMed/NCBI

[154] Google Scholar

[ref49] 49. Santhosh RS, Suriyanarayanan B. Plants: a source for new antimycobacterial drugs. Planta Med. 2014;80(1):9–21. pmid:24218370
View Article
PubMed/NCBI
Google Scholar

[156] View Article

[157] PubMed/NCBI

[158] Google Scholar

[ref50] 50. World Health Organization. Classification of diabetes mellitus. Geneva: World Health Organization. 2019.

[ref51] 51. Salmerón-Manzano E, Garrido-Cardenas JA, Manzano-Agugliaro F. Worldwide Research Trends on Medicinal Plants. Int J Environ Res Public Health. 2020;17(10):3376. pmid:32408690
View Article
PubMed/NCBI
Google Scholar

[161] View Article

[162] PubMed/NCBI

[163] Google Scholar

[ref52] 52. Ighodaro OM, Adeosun AM, Akinloye OA. Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies. Medicina (Kaunas). 2017;53(6):365–74. pmid:29548636
View Article
PubMed/NCBI
Google Scholar

[165] View Article

[166] PubMed/NCBI

[167] Google Scholar

[ref53] 53. Calabrese EJ, Baldwin LA. Hormesis: U-shaped dose responses and their centrality in toxicology. Trends Pharmacol Sci. 2001;22(6):285–91. pmid:11395156
View Article
PubMed/NCBI
Google Scholar

[169] View Article

[170] PubMed/NCBI

[171] Google Scholar

[ref54] 54. Jodynis-Liebert J, Kujawska M. Biphasic Dose-Response Induced by Phytochemicals: Experimental Evidence. J Clin Med. 2020;9(3):718. pmid:32155852
View Article
PubMed/NCBI
Google Scholar

[173] View Article

[174] PubMed/NCBI

[175] Google Scholar

[ref55] 55. Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, et al. Diabetes and lipid metabolism. Hormones (Athens). 2018;17(1):61–7. pmid:29858856
View Article
PubMed/NCBI
Google Scholar

[177] View Article

[178] PubMed/NCBI

[179] Google Scholar

[ref56] 56. Jialal I, Singh G. Management of diabetic dyslipidemia: An update. World J Diabetes. 2019;10(5):280–90. pmid:31139315
View Article
PubMed/NCBI
Google Scholar

[181] View Article

[182] PubMed/NCBI

[183] Google Scholar

[ref57] 57. Schotz MC, Scanu A, Page IH. Effect of triton on lipoprotein lipase of rat plasma. Am J Physiol. 1957;188(2):399–402. pmid:13411223
View Article
PubMed/NCBI
Google Scholar

[185] View Article

[186] PubMed/NCBI

[187] Google Scholar

[ref58] 58. Millar JS, Cromley DA, McCoy MG, Rader DJ, Billheimer JT. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res. 2005;46(9):2023–8. pmid:15995182
View Article
PubMed/NCBI
Google Scholar

[189] View Article

[190] PubMed/NCBI

[191] Google Scholar

[ref59] 59. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50 Suppl(Suppl):S189–94. pmid:19064999
View Article
PubMed/NCBI
Google Scholar

[193] View Article

[194] PubMed/NCBI

[195] Google Scholar

[ref60] 60. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285–350.
View Article
Google Scholar

[197] View Article

[198] Google Scholar

Figures

Abstract

Introduction

Materials and methods

Plant material

General experimental procedures

Extraction and isolation

Antimycobacterial activity

Mycobacterial species used and inoculum preparation.

Microplate alamar blue assay.

Experimental animals and ethical considerations

Acute toxicity of TxAcE

Hypoglycemic effect of TxAcE

Hypolipidemic effect of TxAcE

Biochemical analysis.

Statistical analysis

Results and discussion

Structural characterization of isolated compounds

Antimycobacterial activity

Acute toxicity of TxAcE

TxAcE improves glucose and lipid profiles in diabetic mice

Effect of TxAcE on Triton WR-1339-induced hyperlipidemia

Conclusion

Supporting information

S1 Fig. 1H NMR spectrum of mixture of 1a and 1a’ (500 MHz, CDCl3).

S2a Fig. 13C NMR spectrum of mixture of 1a and 1a’ (125 MHz, CDCl3).

S2b Fig. 13C NMR spectrum of mixture of 1a and 1a’ (125 MHz, CDCl3).

S3 Fig. COSY spectrum of mixture of 1a and 1a’ (500 MHz, CDCl3).

S4 Fig. TOCSY spectrum of mixture of 1a and 1a’ (500 MHz, CDCl3).

S5a Fig. HSQC spectrum of mixture of 1a and 1a’ (500 MHz, CDCl3).

S5b Fig. HSQC spectrum of mixture of 1a and 1a’ (500 MHz, CDCl3).

S6a Fig. HMBC spectrum of mixture of 1a and 1a’ (500 MHz, CDCl3).

S6b Fig. HMBC spectrum of mixture of 1a and 1a’ (500 MHz, CDCl3).

S6c Fig. HMBC spectrum of mixture of 1a and 1a’ (500 MHz, CDCl3).

S7 Fig. ROESY spectrum of mixture of 1a and 1a’ (500 MHz, CDCl3).

S8 Fig. HRMS-ESI spectrum (positive ion mode) of mixture of 1a and 1a’.

S1 File. Values behind the means used to build graphs and tables.

Acknowledgments

References

S1 Fig. ¹H NMR spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

S2a Fig. ¹³C NMR spectrum of mixture of 1a and 1a’ (125 MHz, CDC_l3).

S2b Fig. ¹³C NMR spectrum of mixture of 1a and 1a’ (125 MHz, CDCl3).

S3 Fig. COSY spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

S4 Fig. TOCSY spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

S5a Fig. HSQC spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

S5b Fig. HSQC spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

S6a Fig. HMBC spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

S6b Fig. HMBC spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

S6c Fig. HMBC spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).

S7 Fig. ROESY spectrum of mixture of 1a and 1a’ (500 MHz, CDC_l3).